Skip to content

Effect of oxycodone on intra-abdominal pressure in patients undergoing sepsis surgery due to intra-abdominal infection

Effect of oxycodone on intra-abdominal pressure in patients undergoing sepsis surgery due to intra-abdominal infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102825
Enrollment
Unknown
Registered
2025-05-20
Start date
2025-05-20
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis results from an abdominal infection

Interventions

Oxycodone group:1.5 mg/kg oxycodone was diluted in normal saline to 50 ml and continuously pumped at 0.03-0.06 mg/kg/h (1-2 ml/h) .
Rufentanil group:50ug/kg remifentanil diluted to 50ml with saline, infused at 1.0-2.0ug/kgh (1-2ml/h).

Sponsors

Xuzhou Medical University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 or older 2. Patients with sepsis due to gastrointestinal perforation and treated surgically, and then admitted to the ICU and mechanically ventilated postatively. 3.Indications for analgesia and sedation 4. ASA grade I-III 5. Those who agree to participate in the trial and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. History of dependence on psychotropic drugs and Alcohol 2. Severe cardiovascular and cerebrovascular diseases, kidney and liver diseases before onset 3. Intervention with other sedative or analgesic medications within 1 week before enrolment 4 . Suffering from schizophrenia, epilepsy, Parkinson's syndrome, myasthenia gravis 5. Dependence on opioids, allergies, contraindications to research drugs

Design outcomes

Primary

MeasureTime frame
Intra-abdominal pressure;

Secondary

MeasureTime frame
C-reactive protein;Duration of mechanical ventilation;Incidence of other adverse events (dizziness, headache, drowsiness and other complications) .;Incidence of nausea and vomiting at 24 h after oxycodone/Remifentanil administration.;Plasma albumin;Length of stay in ICU;White blood cells;Neutrophil/lymphocyte;Liver and kidney function;Blood protein input.;

Countries

China

Contacts

Public ContactZhao Wenjing

Affiliated Hospital of Xuzhou Medical University

zhaowj886@sina.com+86 138 5215 7285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026